MCED vs. SCED: Can a Blood Test Detect Breast Cancer Early?

For many women, breast cancer screening begins with a mammogram. Mammograms remain the standard of care and save lives through early detection. But for women with dense breasts, screening can sometimes feel more complicated.

You may have heard about blood tests that claim to detect cancer. Are they real? How do they work? And can they help detect breast cancer earlier?

Here's what women should know.

MCED vs. SCED Blood Tests

Cancer blood tests are generating excitement across healthcare.

The idea is compelling: a simple blood draw that can help identify cancer before symptoms appear.

Not all cancer blood tests are designed to answer the same question. Two emerging approaches are Multi-Cancer Early Detection (MCED) and Single-Cancer Early Detection (SCED) testing.

MCED tests are designed to look for signals associated with multiple types of cancer from a single blood sample. Many of these tests analyze fragments of DNA or other molecular signals circulating in the bloodstream. Their goal is to help identify cancers, including some that don't currently have routine screening options.

SCED tests take a more focused approach. Instead of looking for many different cancers, they concentrate on one specific cancer, allowing researchers to develop technologies around that cancer's unique biology.

Why does this difference matter?

Not every cancer behaves the same way. Some release more detectable material into the bloodstream than others. In early-stage breast cancer, for example, tumors may release very little DNA, making detection more challenging for certain blood-based technologies.

Neither approach is automatically better in every situation. What matters is how well a test performs for the specific cancer you're concerned about, particularly in its earliest stages.

For women who want to make informed decisions about their breast health, understanding that distinction is an important first step.

What Is an MCED Blood Test?

MCED stands for Multi-Cancer Early Detection.

These tests are designed to identify signals from many different cancers using a single blood sample.

Most MCED technologies like the Grail Galleri® or the Exact Sciences CancerGuard® tests analyze fragments of DNA or RNA circulating in the bloodstream.

The goal is ambitious: detect dozens of cancers simultaneously.

Researchers and healthcare leaders see enormous potential in this approach because many cancers currently have no routine screening options.

However, broad detection creates challenges.

The Challenge with MCEDs

Detecting many cancers with one test means balancing sensitivity (the ability of a test to correctly identify those with the condition), specificity (the ability of a test to correctly identify those without the condition), and clinical usefulness across very different tumor types.

Not all cancers behave the same way biologically.

Some cancers release large amounts of detectable DNA into the bloodstream.

Others release very little.

Breast cancer has been one of the more difficult cancers for many DNA-based MCED platforms to detect consistently at early stages.

This challenge has been highlighted by researchers evaluating large MCED studies and discussed extensively in recent conversations around the future of breast cancer detection. ^1,2

The question isn't whether MCEDs have potential.

The question is whether a single biological approach can work equally well for every cancer.

Increasingly, many experts believe the answer may be no.

What Are SCED Tests?

SCED stands for Single-Cancer Early Detection.

Instead of trying to detect dozens of cancers simultaneously, SCEDs focus on one specific cancer.

This allows researchers to design tests around the unique biology of that cancer.

The strategy is similar to how traditional screening works today.

We don't use one test for breast cancer, colon cancer, and cervical cancer.

We use different tools because different cancers behave differently.

The same principle may apply to blood-based detection.

Why SCEDs May Drive Earlier Progress

MCEDs remain an exciting area of innovation.

But many of the most clinically successful blood-based screening tests today are focused on individual cancers. For example, the Guardant Shield™ blood test was developed specifically for colorectal cancer.

It has received significant clinical recognition because they were designed around the biology of one disease rather than many.

This focused approach can make it easier to optimize performance and demonstrate clinical utility.

Why Breast Cancer May Require a Different Strategy

As discussed in the article on genomic and proteomic testing, breast cancer often sheds relatively small amounts of tumor DNA during early stages.

That means many DNA-focused detection approaches may face biological limitations.

Rather than forcing breast cancer into a broader multi-cancer framework, some researchers are pursuing approaches designed specifically around breast cancer biology.

This is where SCEDs become particularly important.

How Is a Breast-Specific Blood Test Different from an MCED Test?

When your priority is breast health, it makes sense to ask whether a test designed specifically for breast cancer might offer advantages over one that looks for many different cancers.

The distinction comes down to focus and biology.

Many MCED tests look for cancer-related signals, such as fragments of DNA circulating in the bloodstream from the tumor. But not all cancers release the same amount of detectable material, particularly in their earliest stages.

Breast cancer can be especially challenging because early-stage tumors may release very little DNA into the blood.

A breast-specific test takes a more targeted approach. By concentrating on the biology of one cancer, researchers can develop and evaluate technologies specifically for detecting that disease.

This doesn't mean every breast-specific test is automatically more accurate than an MCED test. Performance depends on the technology, clinical evidence, and population being tested.

The takeaway? When evaluating a blood test for breast cancer, look beyond how many cancers it can detect. Ask how well it performs specifically for breast cancer, especially at earlier stages.

Certitude®: A Breast Cancer-Specific Approach

For women who take a proactive approach to their health, having access to meaningful information can make a difference in how confidently they navigate their care.

Certitude is a Single-Cancer Early Detection (SCED) blood test developed specifically for breast cancer, with a focus on women with dense breasts.

Unlike tests that rely primarily on tumor DNA, Certitude uses advanced proteomic technology to analyze thousands of proteins in the blood, identifying patterns associated with breast cancer.

It's an innovative approach designed to provide another layer of insight alongside existing breast screening.

What does the clinical evidence show?

According to Certitude validation data³:

• 90% sensitivity: The test correctly identifies approximately 90 out of 100 people who have breast cancer.

• Greater than 99% negative predictive value in women with dense breasts: In the population studied, a negative result was associated with a greater than 99% probability of not having breast cancer.

These results are encouraging, although no test is perfect. A negative result cannot completely rule out breast cancer, and a positive result requires appropriate medical follow-up.

For women with dense breasts, Certitude offers a blood-based option designed to support conversations with their healthcare providers about screening results and next steps.

Because proactive breast health isn't about adding more tests. It's about having the right information to make informed decisions with confidence.

Certitude complements recommended breast screening. It does not replace mammograms, diagnostic imaging, or other follow-up your healthcare provider recommends.

The Future of Blood-Based Detection

MCEDs represent an exciting frontier with the potential to transform cancer screening.

At the same time, SCEDs demonstrate the value of designing tests around the unique biology of individual cancers.

For breast cancer, especially in women with dense breasts, that distinction may be particularly important.

Because when it comes to early detection, understanding the biology is often the first step toward better answers.

Talk with your healthcare provider about your breast cancer screening options and whether additional tools may be appropriate for you.